

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3526193

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	HUMANZYME LIMITED	03/01/2012
RECEIVING PARTY DATA		
Name:	HUMANZYME INC.	
Street Address:	2201 WEST CAMPBELL PARK DRIVE	
Internal Address:	SUITE 24	
City:	CHICAGO	
State/Country:	ILLINOIS	
Postal Code:	60612	
PROPERTY NUMBERS Total: 2		
	Property Type	Number
	Application Number:	13408874
	Application Number:	61448107
CORRESPONDENCE DATA		
Fax Number:	(608)258-4258	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	608 258-4285	
Email:	ipdocketing@foley.com, lmanderson@foley.com	
Correspondent Name:	REBECCA L. HAYS	
Address Line 1:	FOLEY & LARDNER LLP	
Address Line 2:	150 EAST GILMAN STREET	
Address Line 4:	MADISON, WISCONSIN 53703	
ATTORNEY DOCKET NUMBER:	108973-0121	
NAME OF SUBMITTER:	REBECCA L. HAYS	
SIGNATURE:	/Rebecca Hays/	
DATE SIGNED:	09/15/2015	
Total Attachments: 3		
source=Humanzyme Ltd. to Humanzyme Inc#page1.tif		
source=Humanzyme Ltd. to Humanzyme Inc#page2.tif		
source=Humanzyme Ltd. to Humanzyme Inc#page3.tif		

PATENT ASSIGNMENT

WHEREAS, Humanzyme Limited, of Walker House 87 Mary Street, George Town Grand Cayman KY 1-9001, ("Assignor"), is the owner of the patents and patent applications listed on the attached schedule ("Schedule").

WHEREAS, Humanzyme Inc. of 2201 West Campbell Park Drive, Suite 24, Chicago, IL 60612, ("Assignee"), is desirous of acquiring the patents and patent applications set forth in the attached Schedule.

WHEREAS, Assignor is desirous of transferring to Assignee its entire right, title and interest in and to said patents, applications, and inventions.

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor by these presents does sell, assign, transfer and convey unto Assignee, its successors, assigns and legal representatives, the entire, right, title and interest:

(a) in and to said inventions as described in the patents and applications, for the territory of the United States and its possessions and territories and all foreign countries;

(b) in and to the patents and applications and any and all related United States and foreign patent applications disclosing said inventions, including provisionals, nonprovisionals, divisions, continuations, continuations-in-part, and continued prosecution applications and any other related United States and foreign patent applications thereof, along with all rights of priority created by said patent applications under the Paris Convention, and any other treaty relating thereto;

(c) in and to all United States and foreign patents which may be granted on any and all of said patent applications, including extensions, reissues and reexamination certificates thereof; and

(d) in and to all rights to sue for and damages resulting from past, present and future infringement of all United States and foreign patents granted or to be granted on said applications and inventions disclosed therein, and related patents and/or patent applications including extensions, reissues, and reexamination certificates thereof;


said inventions, applications, and rights to damages to be held and enjoyed by the above-named ASSIGNEE, for ASSIGNEE's own use and benefit, and for ASSIGNEE's legal representatives and assigns to the full end of the term or terms for which said patents may be granted, as fully and entirely as the same would have been held by the undersigned ASSIGNOR had this assignment and sale not been made.


Upon request of Assignee, and without further remuneration, Assignor will execute any and all papers desired by Assignee for the filing and granting of patent applications and the perfecting of title thereto in Assignee.

IN WITNESS WHEREOF, a duly authorized officer of Assignor and Assignee has executed this agreement on the date listed below.

Humanzyme Limited

Humanzyme Inc.

By: 

By: 

Name: Scott E. Colver

Name: Scott E. Colver

Title: CEO

Title: CEO

Date: 3/1/12

Date: 3/1/12

Date: 3/1/12

Witness: 

**SCHEDULE FOR ASSIGNMENT OF PATENTS
HUMANZYME LIMITED TO HUMANZYME INC.**

THERMOSTABLE VARIANTS OF FIBROBLAST GROWTH FACTORS

<u>Country</u>	<u>App No.</u>	<u>Patent No.</u>
US	61/448,107	